Back to Journals » Drug Design, Development and Therapy » Volume 17

TMF Inhibits miR-29a/Wnt/β-Catenin Signaling Through Upregulating Foxo3a Activity in Osteoarthritis Chondrocytes [Retraction]

Authors Huang X, Chen Z, Shi W, Zhang R, Li L , Liu H , Wu L 

Received 6 April 2023

Accepted for publication 6 April 2023

Published 7 April 2023 Volume 2023:17 Pages 1063—1064

DOI https://doi.org/10.2147/DDDT.S416064



Huang X, Chen Z, Shi W, et al. Drug Des Devel Ther.2019;13:2009–2019.

The Editor and Publisher of Drug Design, Development and Therapy are retracting the published article. An investigation raised concerns regarding the duplication of western blot bands in Figure 5B, where the images for Figure 5B IP: IgG; IB: Foxo3a and IP: IgG; IB: TCF4 are duplicated.

The authors cooperated with the investigation and provided data associated with the reported study. However, despite the authors’ assistance, a satisfactory explanation for how the images came to be duplicated could not be provided, and the validity of the published work could not be verified. The decision was made to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.